Organon & Co. (OGN)
NYSE: OGN · IEX Real-Time Price · USD
19.61
+0.11 (0.56%)
May 3, 2024, 4:00 PM EDT - Market closed
Organon & Co. Revenue
Organon & Co. had revenue of $6.35B in the twelve months ending March 31, 2024, with 3.29% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.62B with 5.46% year-over-year growth. In the year 2023, Organon & Co. had annual revenue of $6.26B with 1.44% growth.
Revenue (ttm)
$6.35B
Revenue Growth
+3.29%
P/S Ratio
0.79
Revenue / Employee
$634,700
Employees
10,000
Market Cap
5.01B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Option Care Health | 4.43B |
| Bausch + Lomb | 4.31B |
| R1 RCM | 2.25B |
| Lantheus Holdings | 1.37B |
| Merit Medical Systems | 1.28B |
| Haemonetics | 1.27B |
| Halozyme Therapeutics | 829.25M |
| CRISPR Therapeutics AG | 371.21M |
OGN News
- 2 days ago - Organon Reports Results for the First Quarter Ended March 31, 2024 - Business Wire
- 26 days ago - Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 - Business Wire
- 26 days ago - Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints - Business Wire
- 2 months ago - Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary - Business Wire
- 2 months ago - Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Business Wire
- 3 months ago - Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 - Business Wire
- 4 months ago - Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook - Business Wire
- 4 months ago - 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria - Market Watch